Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aspirin and stroke prevention.

J van Gijn1, A Algra

  • 1Department of Neurology, University Medical Centre, Room G03.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. J.vanGijn@neuro.azu.nl

Thrombosis Research
|November 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex differences in intracranial and extracranial atherosclerosis in patients with acute ischemic stroke.

International journal of stroke : official journal of the International Stroke Society·2020
Same author

Timing of procedural stroke and death in asymptomatic patients undergoing carotid endarterectomy: individual patient analysis from four RCTs.

The British journal of surgery·2020
Same author

Gadolinium Enhancement of the Aneurysm Wall in Unruptured Intracranial Aneurysms Is Associated with an Increased Risk of Aneurysm Instability: A Follow-Up Study.

AJNR. American journal of neuroradiology·2019
Same author

Genetic determinants of activity and antigen levels of contact system factors.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Effect of magnesium on cognition after aneurysmal subarachnoid haemorrhage in a randomized trial.

European journal of neurology·2018
Same author

Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study.

Journal of thrombosis and haemostasis : JTH·2017

Aspirin effectively reduces vascular events in arterial disease, though less so in ischemic cerebrovascular disease. Doses between 30-1300 mg daily show similar efficacy, but higher doses increase side effects.

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Pharmacology

Background:

  • Aspirin is a widely used antiplatelet agent for preventing vascular events.
  • Its efficacy and optimal dosage in various arterial diseases, particularly ischemic cerebrovascular disease, require ongoing evaluation.
  • Comparative effectiveness against other antiplatelet agents remains a key area of research.

Purpose of the Study:

  • To analyze the efficacy of aspirin in reducing major vascular events across different arterial disease populations.
  • To compare aspirin's effectiveness with other antiplatelet agents.
  • To investigate the relationship between aspirin dosage and both efficacy and side effects.

Main Methods:

  • Meta-analysis of existing studies on aspirin and other antiplatelet agents.

Related Experiment Videos

  • Comparison of relative risk reduction for vascular events in different patient groups.
  • Evaluation of dose-response relationships for aspirin efficacy and safety.

    • Main Results:

    • Aspirin shows a 19% relative risk reduction in major vascular events for general arterial disease, but only 13% for ischemic cerebrovascular disease.
    • No significant difference in efficacy was found across a wide range of aspirin doses (30-1300 mg daily).
    • Higher aspirin doses are associated with increased frequency of side effects. Other antiplatelet agents offer no clear advantage over aspirin.

    Conclusions:

    • The observed difference in aspirin's efficacy between general arterial disease and ischemic cerebrovascular disease may stem from pathophysiological differences.
    • Aspirin dosage can be individualized within a broad range (75-1300 mg) without compromising efficacy, while minimizing side effects.
    • Recurrent TIAs during aspirin therapy warrant diagnostic review rather than immediate antiplatelet agent switching.